Home > Back to Publisher > Report Information

HIV: Markets for Diagnostics and Therapeutics

Kalorama Information
October 1, 2008
250 Pages - SKU: KLI1646600

Abstract Table of Contents Search inside this report Related Reports Buy by the Section

Countries covered: Global

The strategic concept of HIV/AIDS diagnosis and therapy is one of the most complex that the healthcare industry has ever seen. In order to cope with the challenges and opportunities of HIV/AIDS diagnostics and therapeutics, companies must think on a global basis. In addition to the basic pathology and complications of HIV/AIDS, there are primarily three focal points for the development of strategy in this area: potential market, epidemiology (HIV/AIDS patient trends) and technology.

In his report HIV Markets for Diagnostics and Therapeutics, anlayst Kenneth Krul, PhD examines these focal points, with an eye to creating a comprehensive look at the market and opportunity for both testing and treatments of HIV. Dr. Krul takes a look at the potential theoretical markets and what will be realistic in the current world healthcare system.

The report contains extensive epidemological statistics for HIV in the following WHO health regiions:

Sub-Saharan Africa
Middle East and North Africa
South and South-East Asia
East Asia
Latin America
Caribbean
Eastern Europe and Central Asia
Western and Central Europe
North America
Oceania

In addition the report contains:

Current Market Sizes for HIV Treatments and Diagnostics in each WHO Health Region (treatment and diagnostic markets)
Profiles of Companies in this Market
Eleven Important Conclusions
Review of Current Treatment Products and Diagnostic Tools.

As with all Kalorama Information reports, this product is the result of primary and secondary research. Interviews with experts, as well as research into company reports, medical literature and government data is included.

TABLE OF CONTENTS CHAPTER ONE: EXECUTIVE SUMMARY

Potential and Realistic Markets
Figure 1-1: “Theoretical” Distribution of HIV Market
Figure 1-2 Realistic Market for HIV/AIDs Diagnostics
Table 1-1: Global Market for HIV/AIDS Diagnostics and Therapeutics: 2008
Table 1-3: Regional HIV/AIDS Statistics: 2001 and 2007
Technology
Key HIV/AIDS Market Issues
Scope and Methodology

CHAPTER TWO: INTRODUCTION AND EPIDEMIOLOGY

HIV/AIDS Complications
HIV/AIDS Epidemiology
Table 2-1: Global Summary of HIV/AIDS Populations: 2007 (Category, Average, Range)
Figure 2-1: Estimated People Living With HIV/AIDS Globally: 1990 - 2007
Figure 2-2: Estimated Number of Adult and Child Deaths Due to AIDS Globally: 1990 - 2007
Figure 2-3: Estimated Incidence of HIV Infection Globally: 1990 - 2007 Sub-Saharan Africa
Table 2-2: Regional HIV/AIDS Statistics (I): 2001 and 2007 (Millions)
Table 2-3: Regional HIV/AIDS Statistics (II): 2001 and 2007
Figure 2-4: Estimated HIV Prevalence Rates (%) in Adults (15 - 49 Years) Globally and in Sub-Saharan Africa: 1990 - 2007
Table 2-4: Adult (Aged 14 - 49 years) HIV Prevalence in Sub-Saharan Countries That Have Recently Conducted Population-Based HIC Studies
Table 2-4 (continued): Adult (Aged 14 - 49 years) HIV Prevalence in Sub- Saharan Countries That Have Recently Conducted Population-Based HIC Studies
Asia
Eastern Europe and Central Asia
The Caribbean
Latin America
North America, Western and Central Europe
Figure 2-5: AIDS Distribution by Race in the United States: 2006
Figure 2-6: Risk Factors Associated with AIDS in Men in the United States: 2006
Table 2-5: Prevalence of HIV Infection in the United States Based on Sample Testing: 2006
Figure 2-5: AIDS Distribution by Race in the United States: 2006
Figure 2-6: Risk Factors Associated with AIDS in Men in the United States: 2006
Figure 2-7: Risk Factors Associated with AIDS in Women in the United States: 2006
The Middle East and North Africa

CHAPTER THREE: HIV/AIDS SCREENING AND DIAGNOSIS

Level 1: Screening
Level 2: Confirmatory Testing
Level 3: Diagnosis
Table 3-1: HIV Screening and Confirmatory Testing Products Approved for Use in the United States as of July 9, 2008
Table 3-2: Conditions Attributable to or Complicated by HIV
Table 3-3: AIDS Indicator Conditions
Level 4: Monitoring Treatment and Prognosis

CHAPTER FOUR: HIV/AIDS THERAPEUTICS

Drug Therapy
Figure 4-1: Binding of HIV to T-Cells
Table 4-1: HIV Entry/Fusion Inhibitors; FDA-Approved and in Development: 2008
Table 4-2: Nucleoside Reverse Transcription Inhibitors (NRTI); FDA-Approved and in Development: 2008
Table 4-3: Non-Nucleoside Reverse Transcription Inhibitors (NNRTI); FDA-Approved and in Development: 2008
Figure 4-3: HIV Integration
Table 4-4: Integrase Inhibitors; FDA-Approved and in Development: 2008
Figure 4-4: HIV Transcription
Figure 4-5: HIV Translation
Figure 4-6: HIV Assembly and Maturation
Table 4-5: Protease Inhibitors (PI)/Maturation Inhibitors (MI); FDA-Approved and in Development: 2008
Pediatric HIV/AIDS
Table 4-6: Anti-HIV Drugs in Development: 2008
Table 4-7: Anti-HIV Drugs Approved for Pediatric Use
Chemokine Therapeutics and HIV
Genes and HIV/AIDS
HIV/AIDS Vaccines

CHAPTER FIVE: MARKET ANALYSIS

Table 5-1: Estimated Theoretical Potential for HIV/AIDS Diagnostics and Therapeutics: 2008
Figure 5-1 HIV/AIDS Market by Major World Regions
Table 5-2: Global Market for HIV/AIDS Diagnostics and Therapeutics: 2008 Technology Key HIV/AIDS Market Issues

CHAPTER SIX: COMPANY SNAPSHOTS

Abbott Laboratories
Abbott Molecular Diagnostics
Bristol-Myers Squibb
Calypte Biomedical Corp.
Celera Diagnostics
Gen-Probe Incorporated
Gilead Sciences
GlaxoSmithKline plc
Luminex Corporation
QIAGEN GmbH
Roche Molecular Systems
Tibotec, Inc. (A Johnson & Johnson Company)
VIRxSYS Corporation

CHAPTER SEVEN: CONCLUSIONS AND STRATEGIC IMPLICATIONS

First Conclusion
Second Conclusion
Third Conclusion
Fourth Conclusion
Fifth Conclusion
Sixth Conclusion
Seventh Conclusion
Eighth Conclusion
Ninth Conclusion
Tenth Conclusion
Eleventh Conclusion

CHAPTER EIGHT: GLOSSARY

More Global Microbiology & Virology Reports

In-Vitro Diagnostics (IVD) Market (Clinical Chemistry, Immunoassays, Molecular Diagnostics, Hematology Analyzers & Microbiology Culture) – Global Trends & Forecasts to 2016 by MarketsandMarkets
The global in-vitro diagnostics (IVD) market was valued at $44 billion in 2011 and is expected to have a modest growth during the study period. ...

2012 Global Transfusion Diagnostic Testing Market Overview: Facilities, Test Volumes, and Sales Forecasts for Typing, Grouping and Infectious Disease Screening Tests by Country by Venture Planning Group
This report provides a worldwide overview of the transfusion testing market, including estimates of facilities performing transfusion testing tests, as well as test volume, reagent ...

2012 World Infectious Disease Testing Market Overview: Facilities, Test Volumes, and Sales Forecasts by Country by Venture Planning Group
This report provides a worldwide overview of the infectious disease testing market environment, structure, size and growth. Includes estimates of the number of laboratories ...

2012 Global Malaria Diagnostics Market Outlook: Test Volume and Sales Forecasts by Country and Market Segment by Venture Planning Group
The report presents a detailed analysis of the Malaria diagnostics market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan. Current scientific ...

2012 Global Infectious Disease Testing Market Outlook: Growth Opportunities and Strategies by Venture Planning Group
The infectious disease testing market is one of the most rapidly growing segments of the in vitro diagnostics industry, and the greatest challenge facing suppliers ...

See all reports like this >>

HIV: Markets for Diagnostics and Therapeutics

Share this report

Other tasks

Research Assistance

Related Markets

Microbiology & Virology Reports

Free Alert Me service